Detailed characterization of pre-existing circulating CD8+ T cells with a brain residency-associated phenotype could pave the way for the development of new therapeutic approaches to modulate the contribution of brain CD8+ TRM cells to early but also advanced progressive MS. The gene discussed is CD8A; the disease is myeloid sarcoma.